Cure trials rise while AI tool capture consolidates

Global active cure-related trials now total 21,146, with 78 new wire signals and 28 new cure research items added in the last 24 hours—an encouraging throughput snapshot for both science and execution. On the technology side, a 16,893-session benchmark showed that major AI coding agents differ materially in behavior, while Nvidia’s reported $12.9B acquisition of Hugging Face signals tightening control of model access—consolidation that can narrow the path from tools to discovery. Meanwhile, cure progress arrived through concrete regulatory and trial milestones, including China’s approval of Lumirix® for an additional atopic dermatitis indication and the FDA approval of Ionis’ zanvastro (zilganersen) as a disease-modifying targeted therapy for Alexander disease. The signals rhyme: better therapeutics are moving, but the infrastructure for accelerating R&D is being re-shaped—so the practical task is to keep widening access, verify downstream effects, and keep trials translating into approved treatments. The window is still open.